Strategic partnerships between biotech innovators, VCs and pharmaceutical companies have become the cornerstone of drug development, illustrating a beneficial exchange where cutting-edge research meets robust resources. This session delves into the transformative potential of these partnerships through the exploration of real-world experiences between Novartis and its partners. Panelists will share valuable insights and key learnings from the stages of diligence, negotiation, funding, and alliance management that has continued to allow these relationships to drive industry success and innovation.